spacer
home > ebr > autumn 2009 > primum non nocere: first, do no harm
PUBLICATIONS
European Biopharmaceutical Review

Primum non nocere: First, do no harm

 

Ever since the publication of the report, ‘To Err is Human; Building a Safer Health System’, the medical world has begun to open its eyes to the magnitude and impact of errors (1). The report was issued in 1999 by the Institute of Medicine (IOM) of the National Academy of Sciences in the US, and called for a broad effort to improve the situation, which included the reporting of errors and adverse events. With the latter, we mean an injury related to care (diagnosis, treatment, failure, systems and equipment used). The world needed some time to accept that in the Western, more people die due to preventable errors in hospitals than by traffic accidents, or other situations which are generally perceived as being more dangerous.

This report was certainly not the only one published and many followed. In the Netherlands, for example, the President Director of Shell Netherlands, Mr Rein Willems, published a report in 2004 which included four ways to reduce errors by no less than 75 per cent within a period of 15 years. Willems claimed the necessity of the introduction of a certified clinical risk management system and strong governmental supervision.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Gian Schiava is Marketing Manager at The Patient Safety Company, where he works on the international expansion of this Dutch company. He has more than 20 years of marketing and sales experience in various industries, varying from office furniture to heavy-duty forklifts. As a member of the Management Team, he is interested in the current challenge to market products that lead to a reduction of incidents and improved patient safety levels, both in large medical hospitals and smaller, specialised healthcare organisations. Gian holds a Bachelor in Economics and undertook post-doctoral studies.
spacer
Gian Schiava
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Trilogy Writing & Consulting Gains PIF TICK Accreditation To Be Recognised As A ‘Trusted Information Creator’


More info >>

White Papers

7 Common Myths about QP Training Debunked: A Guide for Senior Managers

RSSL

The role of the Qualified Person (QP) in the pharmaceutical industry is mandated by law (Directive 2001/83/EC, Directive 2001/20/EC, UK SI 2012/1916, UK SI 2004/103). Every holder of a relevant Manufacturers Authorisation (human and veterinary) must have at least one QP; without one, no batch of medicinal product can be certified for release for sale.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement